2026-06-01T11:51:41Zhttps://riuma.uma.es/rest/oai/requestoai:riuma.uma.es:10630/272492026-02-03T12:01:14Zcom_10630_2254col_10630_37959
Testing exosomes as a treatment for posthemorrhagic hydrocephalus.
López-de-San-Sebastián, Javier
Rodríguez-Pérez, Luis Manuel
Anguita-Guardia, Alba
Jiménez-Lara, Antonio Jesús
Páez-González, Patricia
Hidrocefalia - Tratamiento
Terapia celular - Ensayos
Germinal matrix hemorrhages and intraventricular hemorrhages (GMH/IVH) lead to posthemorrhagic hydrocephalus (PHH), a severe cause of morbidity and mortality in premature neonates. GMH/IVH disrupts the ependyma, which forms a physical and functional barrier between the brain parenchyma and the cerebrospinal fluid (CSF). CSF circulation and physiology is also affected by ependyma disruption. Thus, ependyma is a key target when designing PHH treatments. Despite this, hydrocephalus treatments are surgical and focused on alleviating ventricular pressure by draining CSF. No therapy is currently aimed to recover the ependyma. Nevertheless, bone marrow derived mesenchymal stem cells (MSCs) are known to be great agents when dealing with inflammation. Also, exosomes have proven to be promising tools when designing anti-inflammatory treatments. Therefore, gaining insight in the treating capabilities of MSCs exosomes in PHH can be valuable.
Results
Differential effects in edema progression and ependymal cells ciliogenesis are found when analyzing treatments with conditioned and non-conditioned exosomes in moderate PHH and severe PHH.
2023-07-14T10:21:13Z
2023-07-14T10:21:13Z
2023-07
2023
conference output
https://hdl.handle.net/10630/27249
eng
2023 Annual Meeting of the Society for Research into Hydrocephalus and Spina Bifida (SRHSB)
Stirling, Reino Unido
Julio 2023
open access